{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:00:25Z","timestamp":1780624825634,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA214263"],"award-info":[{"award-number":["U01 CA214263"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA252965"],"award-info":[{"award-number":["U01 CA252965"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Sheikh Khalifa bin Zayed Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cell Biol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41556-025-01816-5","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:03:02Z","timestamp":1764583382000},"page":"197-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7542-5201","authenticated-orcid":false,"given":"Warapen","family":"Treekitkarnmongkol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1821-0260","authenticated-orcid":false,"given":"Hiroshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5837-2083","authenticated-orcid":false,"given":"Deivendran","family":"Sankaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chee","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanchita","family":"Rauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4565-1534","authenticated-orcid":false,"given":"Tristian","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieko","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1822-4526","authenticated-orcid":false,"given":"Fredrik I.","family":"Thege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moorthy P.","family":"Ponnusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9470-9317","authenticated-orcid":false,"given":"Surinder K.","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-5863","authenticated-orcid":false,"given":"Huamin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2812-8546","authenticated-orcid":false,"given":"Thomas D.","family":"Schmittgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-8942","authenticated-orcid":false,"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-3416","authenticated-orcid":false,"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-9978","authenticated-orcid":false,"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6884-6246","authenticated-orcid":false,"given":"Subrata","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"1816_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible?. Nat. Rev. Drug Discov. 13, 828\u2013851 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1816_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"1816_CR3","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1816_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih, M. G. et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 23, 115\u2013124 (2022).","journal-title":"Lancet Oncol."},{"key":"1816_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler, J. H. et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N. Engl. J. Med. 388, 33\u201343 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1816_CR6","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat. Med. 28, 2171\u20132182 (2022).","journal-title":"Nat. Med."},{"key":"1816_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"1816_CR8","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1816_CR9","doi-asserted-by":"publisher","first-page":"110993","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan, M. B. et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 39, 110993 (2022).","journal-title":"Cell Rep."},{"key":"1816_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","volume":"13","author":"R Yaeger","year":"2023","unstructured":"Yaeger, R. et al. Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer. Cancer Discov. 13, 41\u201355 (2023).","journal-title":"Cancer Discov."},{"key":"1816_CR11","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","volume":"13","author":"MV Negrao","year":"2023","unstructured":"Negrao, M. V. et al. Comutations and KRASG12C inhibitor efficacy in advanced NSCLC. Cancer Discov. 13, 1556\u20131571 (2023).","journal-title":"Cancer Discov."},{"key":"1816_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal, A., Li, B. T. & O\u2019Reilly, E. M. Targeting KRAS in cancer. Nat. Med. 30, 969\u2013983 (2024).","journal-title":"Nat. Med."},{"key":"1816_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2005.01.014","volume":"120","author":"SM Johnson","year":"2005","unstructured":"Johnson, S. M. et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635\u2013647 (2005).","journal-title":"Cell"},{"key":"1816_CR14","first-page":"2453","volume":"31","author":"T Tsunoda","year":"2011","unstructured":"Tsunoda, T. et al. Oncogenic KRAS regulates miR-200c and miR-221\/222 in a 3D-specific manner in colorectal cancer cells. Anticancer Res. 31, 2453\u20132459 (2011).","journal-title":"Anticancer Res."},{"key":"1816_CR15","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1093\/nar\/gkr006","volume":"39","author":"S Galardi","year":"2011","unstructured":"Galardi, S., Mercatelli, N., Farace, M. G. & Ciafre, S. A. NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res. 39, 3892\u20133902 (2011).","journal-title":"Nucleic Acids Res."},{"key":"1816_CR16","doi-asserted-by":"publisher","first-page":"102500","DOI":"10.1016\/j.jiac.2024.08.015","volume":"31","author":"W Zhang","year":"2024","unstructured":"Zhang, W. & Li, P. The suppression of nuclear factor kappa B\/microRNA 222 axis alleviates lipopolysaccharide-induced acute lung injury through increasing the alkylglyceronephosphate synthase expression. J. Infect. Chemother. 31, 102500 (2024).","journal-title":"J. Infect. Chemother."},{"key":"1816_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1158\/1940-6207.CAPR-20-0303","volume":"14","author":"RL Dittmar","year":"2021","unstructured":"Dittmar, R. L. et al. Plasma miRNA biomarkers in limited volume samples for detection of early-stage pancreatic cancer. Cancer Prev. Res. 14, 729\u2013740 (2021).","journal-title":"Cancer Prev. Res."},{"key":"1816_CR18","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.gastha.2024.08.002","volume":"3","author":"W Treekitkarnmongkol","year":"2024","unstructured":"Treekitkarnmongkol, W. et al. Blood-based microRNA biomarker signature of early-stage pancreatic ductal adenocarcinoma with lead-time trajectory in prediagnostic samples. Gastro Hep. Adv. 3, 1098\u20131115 (2024).","journal-title":"Gastro Hep. Adv."},{"key":"1816_CR19","doi-asserted-by":"publisher","first-page":"14153","DOI":"10.18632\/oncotarget.3686","volume":"6","author":"Q Xu","year":"2015","unstructured":"Xu, Q. et al. miR-221\/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Oncotarget 6, 14153\u201314164 (2015).","journal-title":"Oncotarget"},{"key":"1816_CR20","doi-asserted-by":"publisher","first-page":"41950","DOI":"10.1074\/jbc.M400086200","volume":"279","author":"M Tanaka","year":"2004","unstructured":"Tanaka, M. et al. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J. Biol. Chem. 279, 41950\u201341959 (2004).","journal-title":"J. Biol. Chem."},{"key":"1816_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/emboj.2010.296","volume":"30","author":"Z Lu","year":"2011","unstructured":"Lu, Z. et al. miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J. 30, 57\u201367 (2011).","journal-title":"EMBO J."},{"key":"1816_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1373\/clinchem.2009.137364","volume":"56","author":"MC du Rieu","year":"2010","unstructured":"du Rieu, M. C. et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin. Chem. 56, 603\u2013612 (2010).","journal-title":"Clin. Chem."},{"key":"1816_CR23","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1182\/blood-2003-07-2452","volume":"103","author":"JW Yam","year":"2004","unstructured":"Yam, J. W., Jin, D. Y., So, C. W. & Chan, L. C. Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein. Blood 103, 1445\u20131453 (2004).","journal-title":"Blood"},{"key":"1816_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aar8371","volume":"11","author":"E Sheffels","year":"2018","unstructured":"Sheffels, E. et al. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation. Sci. Signal 11, eaar8371 (2018).","journal-title":"Sci. Signal"},{"key":"1816_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6171","volume":"5","author":"S Nam","year":"2019","unstructured":"Nam, S. et al. Cell cycle progression in confining microenvironments is regulated by a growth-responsive TRPV4-PI3K\/Akt-p27(Kip1) signaling axis. Sci. Adv. 5, eaaw6171 (2019).","journal-title":"Sci. Adv."},{"key":"1816_CR26","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.3390\/cells10123327","volume":"10","author":"Z Wang","year":"2021","unstructured":"Wang, Z. Regulation of cell cycle progression by growth factor-induced cell signaling. Cells 10, 3327 (2021).","journal-title":"Cells"},{"key":"1816_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/21541248.2019.1611168","volume":"12","author":"E Sheffels","year":"2021","unstructured":"Sheffels, E., Sealover, N. E., Theard, P. L. & Kortum, R. L. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells. Small GTPases 12, 67\u201378 (2021).","journal-title":"Small GTPases"},{"key":"1816_CR28","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","volume":"26","author":"MB Ryan","year":"2020","unstructured":"Ryan, M. B. et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. Clin. Cancer Res. 26, 1633\u20131643 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1816_CR29","first-page":"5192","volume":"14","author":"AG Batzer","year":"1994","unstructured":"Batzer, A. G., Rotin, D., Urena, J. M., Skolnik, E. Y. & Schlessinger, J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol. Cell. Biol. 14, 5192\u20135201 (1994).","journal-title":"Mol. Cell. Biol."},{"key":"1816_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","volume":"4","author":"TJ Hagenbeek","year":"2023","unstructured":"Hagenbeek, T. J. et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat. Cancer 4, 812\u2013828 (2023).","journal-title":"Nat. Cancer"},{"key":"1816_CR31","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.cell.2019.10.037","volume":"179","author":"A Kapoor","year":"2019","unstructured":"Kapoor, A. et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 179, 1239 (2019).","journal-title":"Cell"},{"key":"1816_CR32","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1021\/bi500182x","volume":"53","author":"N Kozer","year":"2014","unstructured":"Kozer, N. et al. Recruitment of the adaptor protein Grb2 to EGFR tetramers. Biochemistry 53, 2594\u20132604 (2014).","journal-title":"Biochemistry"},{"key":"1816_CR33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122531119","volume":"119","author":"CW Lin","year":"2022","unstructured":"Lin, C. W. et al. A two-component protein condensate of the EGFR cytoplasmic tail and Grb2 regulates Ras activation by SOS at the membrane. Proc. Natl Acad. Sci. USA 119, e2122531119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1816_CR34","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","volume":"8","author":"C Fedele","year":"2018","unstructured":"Fedele, C. et al. SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models. Cancer Discov. 8, 1237\u20131249 (2018).","journal-title":"Cancer Discov."},{"key":"1816_CR35","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","volume":"20","author":"RJ Nichols","year":"2018","unstructured":"Nichols, R. J. et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat. Cell Biol. 20, 1064\u20131073 (2018).","journal-title":"Nat. Cell Biol."},{"key":"1816_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0076-6879(07)00401-6","volume":"439","author":"N Radulovich","year":"2008","unstructured":"Radulovich, N., Qian, J. Y. & Tsao, M. S. Human pancreatic duct epithelial cell model for KRAS transformation. Methods Enzymol. 439, 1\u201313 (2008).","journal-title":"Methods Enzymol."},{"key":"1816_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-019-1062-1","volume":"568","author":"W Yao","year":"2019","unstructured":"Yao, W. et al. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature 568, 410\u2013414 (2019).","journal-title":"Nature"},{"key":"1816_CR38","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ccr.2011.12.025","volume":"21","author":"H Katayama","year":"2012","unstructured":"Katayama, H. et al. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 21, 196\u2013211 (2012).","journal-title":"Cancer Cell"},{"key":"1816_CR39","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1053\/j.gastro.2023.12.018","volume":"166","author":"S Parte","year":"2024","unstructured":"Parte, S. et al. Cancer-associated fibroblast induces acinar-to-ductal cell transdifferentiation and pancreatic cancer initiation via LAMA5\/ITGA4 axis. Gastroenterology 166, 842\u2013858 e845 (2024).","journal-title":"Gastroenterology"}],"container-title":["Nature Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41556-025-01816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41556-025-01816-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41556-025-01816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T15:02:21Z","timestamp":1768489341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41556-025-01816-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1816"],"URL":"https:\/\/doi.org\/10.1038\/s41556-025-01816-5","relation":{},"ISSN":["1465-7392","1476-4679"],"issn-type":[{"value":"1465-7392","type":"print"},{"value":"1476-4679","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M. is a consultant for Tezcat Bioscience. A.M. is listed on a patent that had been licensed by Thrive Earlier Detection (an Exact Sciences Company). K.H. is funded by Nanostring Technology. The other authors declare no competing interests. A provisional patent on the clinically relevant findings of this study has been filed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}